Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.

In women with relapsing-remitting MS, a six-month gluten-free diet was found to ease disability and support a healthier body ...

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis No drugs are currently approved to treat this type of MS WEDNESDAY, April 9, 2025 (HealthDay ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

A new report reveals the heavy personal and economic toll of MS and recommends more complete, patient focused approaches to measuring and managing the disease.

Physical activity was associated with a lower risk of disability progression in multiple sclerosis (MS), longitudinal data showed. Compared with low physical activity, the risk of confirmed disability ...

October 12, 2012 (Lyon, France) — Final results of a phase 3 trial comparing 2 doses of teriflunomide (Aubagio, Genzyme/Sanofi), 14 mg/d and 7 mg/d, vs placebo in patients with relapsing multiple ...

Use of oral contraceptives before an MS diagnosis was linked with a lower risk of progression independent of relapse activity (PIRA) in a retrospective study. Contraceptive use delayed a PIRA event by ...

Multiple sclerosis MS book and prescription and pen. An experimental drug can delay disability progression in advanced multiple sclerosis patients Tolebrutinib delayed disability progression by 31% in ...